Sec Form 4 Filing - GOLDMAN SACHS & CO. LLC @ T2 Biosystems, Inc.

Insider filing report for Changes in Beneficial Ownership

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Here is the list of insider trading transaction codes

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

November 30, 2011

Estimated average burden hours per response...

0.5

1. Name and Address of Reporting Person

GOLDMAN SACHS & CO. LLC

2. Issuer Name and Ticker or Trading Symbol
T2 Biosystems, Inc. [ TTOO]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	X __ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

200 WEST STREET

3. Date of Earliest Transaction (MM/DD/YY)
03/24/2020

(Street)

NEW YORK, NY10282

4. If Amendment, Date Original Filed (MM/DD/YY)

6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	03/24/2020		P		500	A	$ 0.378	4,196,956 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	03/24/2020		S		500	D	$ 0.378	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	03/25/2020		P		600	A	$ 0.9279	4,197,056 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	03/25/2020		S		600	D	$ 0.9279	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	04/09/2020		P		1,000	A	$ 0.49	4,197,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	04/09/2020		S		1,000	D	$ 0.49	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		2,655	D	$ 0.52	4,193,801 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		1,000	D	$ 0.521	4,192,801 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		1,000	D	$ 0.526	4,191,801 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		500	D	$ 0.528	4,191,301 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		50	D	$ 0.53	4,191,251 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		500	D	$ 0.5318	4,190,751 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		100	D	$ 0.5325	4,190,651 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		6,256	D	$ 0.54	4,184,395 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		100	D	$ 0.55	4,184,295 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		939	D	$ 0.5503	4,183,356 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		P		26,200	A	$ 0.5517	4,209,556 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		10,100	D	$ 0.57	4,199,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 ) ^{( 2 )} ^{( 3 )}}	05/06/2020		S		2,000	D	$ 0.5701	4,197,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/06/2020		S		1,000	D	$ 0.5702	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/12/2020		P		2,500	A	$ 0.546	4,198,956 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/12/2020		S		2,500	D	$ 0.546	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		200	D	$ 0.8314	4,196,256 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		3,235	D	$ 0.8318	4,193,021 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		2,031	D	$ 0.8325	4,190,990 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		2,031	D	$ 0.8326	4,188,959 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		P		10,328	A	$ 0.8329	4,199,287 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		800	D	$ 0.8345	4,198,487 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/19/2020		S		2,031	D	$ 0.8347	4,196,456 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}
Common Stock ^{( 1 )} ^{( 2 )} ^{( 3 )}	05/20/2020		P		5,126	A	$ 0.803	4,201,582 ^{( 4 )} ^{( 5 )}	I	See Footnotes ^{( 4 )} ^{( 5 )}

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
( *e.g.* , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (MM/DD/YY)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

**Reporting Owners**
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GOLDMAN SACHS & CO. LLC 200 WEST STREET NEW YORK, NY10282		X
GOLDMAN SACHS GROUP INC 200 WEST STREET NEW YORK, NY10282		X

**Signatures**
/s/ Jamison Yardley, Attorney-in-fact		08/03/2021
Signature of Reporting Person		Date
/s/ Jamison Yardley, Attorney-in-fact		08/03/2021
Signature of Reporting Person		Date

Explanation of Responses:

( 1 )These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
( 2 )Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
( 3 )This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs (together, with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group.
( 4 )GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
( 5 )Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Remarks:
Balance of trades included in attached schedule. (See Exhibit 99.1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sec Form 4 Filing - GOLDMAN SACHS & CO. LLC @ T2 Biosystems, Inc. - 2020-03-24